A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) (NCT07549412)
A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
🩺 Plain-English Summary (8th-Grade Level)
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluoride/tipiracil (FTD-TPI) plus bevacizumab.
Who can join: Review the eligibility criteria below.
Location: Rocky Mountain Cancer Centers, LLP- Aurora — Lone Tree, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (34 Sites)
Showing the first 25 of 34 sites.
- Rocky Mountain Cancer Centers, LLP- Aurora — Lone Tree, Colorado
- Florida Cancer Specialists-Broadway — Fort Myers, Florida
- Florida Cancer Specialists - St. Petersburg Bayfront — St. Petersburg, Florida
- Florida Cancer Specialists East - FCS EAST - West Palm Beach — West Palm Beach, Florida
- Illinois Cancer Specialists — Arlington Heights, Illinois
- Illinois CancerCare PC — Peoria, Illinois
- Springfield Clinic — Springfield, Illinois
- Profound Research LLC at Cancer and Leukemia Center — Sterling Heights, Michigan
- Minnesota Oncology Hematology, P.A. — Saint Louis Park, Minnesota
- Missouri Cancer Associates - 150518964 — Columbia, Missouri
- SCRI Oncology Partners — Nashville, Tennessee
- Texas Oncology, P.A. - Abilene - 300210366 — Abilene, Texas
- Texas Oncology-South Austin — Austin, Texas
- Texas Oncology DFW — Bedford, Texas
- Texas Oncology- San Antonio — San Antonio, Texas
- Texas Oncology, P.A. - Tyler — Tyler, Texas
- Virginia Oncology Associates — Newport News, Virginia
- Blue Ridge Cancer Care - 300202915 — Roanoke, Virginia
- GenesisCare North Shore (Oncology) — St Leonards, New South Wales
- Icon Cancer Centre Chermside — Chermside, Queensland
- Mater Misericordiae Ltd - PARENT — South Brisbane, Queensland
- Flinders Medical Centre — Bedford Park, South Australia
- University Health Network - Princess Margaret Cancer Centre — Toronto, Ontario
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong
- Sichuan Cancer Hospital — Chengdu, Sichuan
📞 Contact the Study Coordinator
Phone: (888) 275-7376
Email: eMediUSA@emdserono.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Colorectal Cancer
- A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer — Phoenix, Arizona
- Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer — Toronto, Ontario
- A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) — Los Angeles, California
- A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer — Duarte, California
- A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer — Los Angeles, California
- Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation — Phoenix, Arizona
Explore by condition: All Metastatic Colorectal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.